Highlights Modalis Therapeutics Corporation

Equities

4883

JP3922600006

Delayed Japan Exchange Other stock markets 04:53:48 16/05/2024 BST			5-day change	1st Jan Change
67 ^JPY	-4.29%		-9.33%	-45.16%

05-07	Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101	CI
04-30	Modalis Therapeutics Corporation to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy at the Global Cell & Gene Therapy Summit	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101	05-07	CI
Modalis Therapeutics Corporation to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy at the Global Cell & Gene Therapy Summit	04-30	CI
Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs	04-15	MT
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership	12-13	MT
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement	12-12	CI
Modalis Therapeutics Corporation to Regain Full Rights to MDL-201 and MDL-202 from Astellas Pharma Inc	07/08/23	CI
Modalis Therapeutics Corporation Receives Positive FDA Response for Pre-IND Review for MDL-101 Clinical Development	26/06/23	CI
Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Modalis Therapeutics Corporation to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of A Type of Muscular Dystrophy At the ASGCT Annual Meeting	19/04/23	CI
Modalis Therapeutics Corporation Announces Notice of Termination of A Research Collaboration on 205	12/01/23	CI
Modalis Therapeutics Swings to Loss in Q1 on Growing Research Costs	10/05/22	MT
Modalis Therapeutics Adds Cardiomyopathy Therapy to In-House Pipeline	10/05/22	MT
Modalis Therapeutics Corporation Announces Addition of MDL-105 to In-house Pipelines	09/05/22	CI
Modalis Therapeutics and Astellas Pharma End Research Collaboration on Nervous System Medication	10/01/22	MT
Modalis Announces Termination of Research Collaboration on MDL-204	07/01/22	CI
Modalis Therapeutics Corporation Receives Notice Regarding the Decision to Apply for New Market Segment “Growth Market”	15/09/21	CI
Modalis Therapeutics Corporation Announces Consolidated Earnings Results for the Six Months Ended June 30, 2021	05/08/21	CI
Modalis Announces Completion of a Research Collaboration on Angelman Syndrome and Regaining Worldwide Rights	05/08/21	CI
Modalis Therapeutics Swings Back to Profit in Q1	06/05/21	MT
Modalis Therapeutics Corporation Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2021	06/05/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Modalis Therapeutics Corporation

Equities

4883

JP3922600006

Highlights

Filters